These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18713849)

  • 21. Future Directions and Resource Needs for National Heart, Lung, and Blood Institute (NHLBI) Gene Therapy Research: A Report of an NHLBI Workshop.
    McDonald CL; Qasba P; Anderson DG; Bao G; Colvin RA; Kohn DB; Malik P; Mitchell MJ; Pu WT; Rawlings DJ; Williams DA; Flotte TR
    Hum Gene Ther; 2023 Feb; 34(3-4):83-89. PubMed ID: 36794978
    [No Abstract]   [Full Text] [Related]  

  • 22. Angiogenesis Research: Extramural Portfolio Supported by the National Heart, Lung, and Blood Institute, 2008-2015.
    Gao Y; Stanley DV; Robinson VC; Reid DM; Galis ZS
    Circ Res; 2017 May; 120(11):1713-1717. PubMed ID: 28546354
    [No Abstract]   [Full Text] [Related]  

  • 23. Lung disease left out in the cold.
    The Lancet Respiratory Medicine
    Lancet Respir Med; 2016 Jul; 4(7):527. PubMed ID: 27396761
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of Sex and Gender on Autoimmune Lung Disease: Opportunities for Future Research: NHLBI Working Group Report.
    Volkmann ER; Siegfried J; Lahm T; Ventetuolo CE; Mathai SC; Steen V; Herzog EL; Shansky R; Anguera MC; Danoff SK; Giles JT; Lee YC; Drake W; Maier LA; Lachowicz-Scroggins M; Park H; Banerjee K; Fessel J; Reineck L; Vuga L; Crouser E; Feghali-Bostwick C
    Am J Respir Crit Care Med; 2022 Oct; 206(7):817-823. PubMed ID: 35549658
    [No Abstract]   [Full Text] [Related]  

  • 25. The ambitions and goals of the National Heart, Lung, and Blood Institute at The National Institute of Health.
    Eur Heart J; 2009 May; 30(10):1155-6. PubMed ID: 19443422
    [No Abstract]   [Full Text] [Related]  

  • 26. Pulmonary research in 2013 and beyond: a National Heart, Lung, and Blood Institute perspective.
    Kiley JP; Senior RM
    Am J Physiol Lung Cell Mol Physiol; 2012 Nov; 303(9):L729-32. PubMed ID: 22962017
    [No Abstract]   [Full Text] [Related]  

  • 27. Thought exercises on accountability and performance measures at the National Heart, Lung, and Blood Institute (NHLBI): an invited commentary for circulation research.
    Lauer MS
    Circ Res; 2011 Feb; 108(4):405-9. PubMed ID: 21335430
    [No Abstract]   [Full Text] [Related]  

  • 28. Portfolio analysis on preeclampsia and pregnancy-associated hypertension research funded by the National Heart, Lung, and Blood Institute.
    Maric-Bilkan C
    Physiol Genomics; 2018 Nov; 50(11):982-987. PubMed ID: 30265594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developing a research agenda for primary prevention of chronic lung diseases--an NHLBI perspective.
    Kiley J; Gibbons G
    Am J Respir Crit Care Med; 2014 Apr; 189(7):762-3. PubMed ID: 24684354
    [No Abstract]   [Full Text] [Related]  

  • 30. Chronic obstructive pulmonary disease resources.
    Mosocco DJ
    Home Healthc Nurse; 2006 Apr; 24(4):202. PubMed ID: 16680046
    [No Abstract]   [Full Text] [Related]  

  • 31. Chronic obstructive pulmonary disease: reactive past, preventive future.
    Sin DD
    Proc Am Thorac Soc; 2009 Sep; 6(6):523. PubMed ID: 19741260
    [No Abstract]   [Full Text] [Related]  

  • 32. NHLBI plans for the promise of cell-based therapies.
    Mondoro TH; Thomas JW; Henslee-Downey PJ; Peterson CM
    Cytotherapy; 2005; 7(4):317-27. PubMed ID: 16162453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanotechnology research support at the National Heart, Lung, and Blood Institute.
    Buxton DB
    Circ Res; 2011 Jul; 109(3):250-4. PubMed ID: 21778434
    [No Abstract]   [Full Text] [Related]  

  • 34. Global Initiative for Chronic Obstructive Lung Diseases (GOLD).
    Hurd S; Pauwels R
    Pulm Pharmacol Ther; 2002; 15(4):353-5. PubMed ID: 12220939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "The Good Old R01": Challenging Downward Funding Success Trends at the National Heart, Lung, and Blood Institute.
    Oh YS; Robinson V; Stanley DV; Tolunay E; Kim DY; Galis ZS
    Circ Res; 2016 May; 118(10):1475-9. PubMed ID: 27174948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peak Inspiratory Flow Rate: An Emerging Biomarker in Chronic Obstructive Pulmonary Disease.
    Mahler DA
    Am J Respir Crit Care Med; 2019 Jun; 199(12):1577-1579. PubMed ID: 30892057
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical research in chronic obstructive pulmonary disease: needs and opportunities.
    Croxton TL; Weinmann GG; Senior RM; Wise RA; Crapo JD; Buist AS
    Am J Respir Crit Care Med; 2003 Apr; 167(8):1142-9. PubMed ID: 12684252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reply to Mahler: Peak Inspiratory Flow Rate: An Emerging Biomarker in Chronic Obstructive Pulmonary Disease.
    Wu AC; Himes BE
    Am J Respir Crit Care Med; 2019 Jun; 199(12):1579. PubMed ID: 30892053
    [No Abstract]   [Full Text] [Related]  

  • 39. Chronic Obstructive Pulmonary Disease: Shifting the Paradigm to the Vasculature.
    Wouters EFM; Franssen FM
    Am J Respir Crit Care Med; 2019 Feb; 199(3):258-259. PubMed ID: 30265129
    [No Abstract]   [Full Text] [Related]  

  • 40. [Systemic features in chronic obstructive pulmonary disease].
    Batura-Gabryel H
    Pneumonol Alergol Pol; 2009; 77(2):180-5. PubMed ID: 19462353
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.